Influenza hemagglutinin-specific B-cell receptor (HA-specific BCR) (HA-specific BCR)

The influenza hemagglutinin-specific B-cell receptor (BCR) is a membrane-bound immunoglobulin complex on the surface of B lymphocytes that plays a central role in the adaptive immune response to influenza viruses [1]. This receptor specifically recognizes and binds to epitopes on the hemagglutinin (HA) protein, the primary surface glycoprotein of the virus responsible for host cell attachment and membrane fusion [4]. Upon antigen binding, the BCR initiates intracellular signaling cascades that lead to B-cell activation, clonal expansion, and the production of secreted antibodies or long-lived memory B cells [1]. These antibodies provide protection by neutralizing the virus, preventing its entry into respiratory epithelial cells, or by mediating effector functions like antibody-dependent cellular cytotoxicity (ADCC) [2]. Therapeutic strategies, including seasonal and universal vaccines, aim to elicit BCRs that target either the highly variable head or the more conserved stem regions of the HA protein to provide broad and lasting immunity [3, 5].

Other names

Anti-hemagglutinin B-cell receptorHA-specific B-cell receptorHemagglutinin-binding B-cell receptorAnti-HA BCRHemagglutinin-specific immunoglobulin

Neutralization of viral infectivity by blocking hemagglutinin-sialic acid binding; inhibition of viral-host membrane fusion; induction of B-cell activation and differentiation into antibody-secreting plasma cells.